Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1342 participants
OBSERVATIONAL
2014-04-30
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety of Cardioversion of Acute Atrial Fibrillation
NCT01380574
Treatment of Atrial Fibrillation in Finland
NCT01990105
Atrial Fibrillation Burden and Long-term Risk of Thromboembolic Complications- the FinCV-4 Study
NCT04001205
Evaluation of Predictive Factors for Recurrence of Persistent Atrial Fibrillation After Ablation
NCT06620575
Atrial Fibrillation Prior and Post Elective Cardioversion
NCT05926401
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Initially, 2373 patients were captured after which all ECV cases were identified and included manually in the study using a structured electronic case report form. The study cohort comprised 1998 ECVs and 1342 patients. Follow-up data was gathered for 30 days after ECV and all strokes, transient ischemic attacks, arrhythmic complications, AF recurrences and failed cardioversions were recorded and subjected to careful exploration. IBM SPSS Statistics software version 22.0 was used to perform all analyses.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pharmacological cardioversions
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Turku
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Juhani Airaksinen
Professor of Cardiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juhani Airaksinen, Professor
Role: PRINCIPAL_INVESTIGATOR
Turku University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Turku University Hospital
Turku, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
T118/2014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.